Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Action On Sexual Supplements Should Spur Better Self-Policing – UNPA

This article was originally published in The Tan Sheet

Executive Summary

The proliferation of erectile dysfunction "dietary supplements" adulterated with prescription drugs should lead the supplement industry to sharpen its capabilities to keep these illegal products off the market, United Natural Products Alliance President Loren Israelsen says

You may also be interested in...



Gaps In Spiked Supplement Net Could Shrink With Non-Targeted Screening

FDA plans to deploy testing technology that casts a wider net than its existing targeted adulterant tests, intending to catch product that may be tainted with as-yet-unknown adulterants.

Gaps In Spiked Supplement Net Could Shrink With Non-Targeted Screening

FDA plans to deploy testing technology that casts a wider net than its existing targeted adulterant tests, intending to catch product that may be tainted with as-yet-unknown adulterants.

FDA Lifts Curtain On The Secret Behind Magic Power Coffee

FDA's consumer advisory against a coffee product that contains an active drug ingredient for erectile dysfunction reflects the agency's growing capability to keep up with noncompliant firms that add drug substances to so-called dietary supplements

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS101295

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel